COST-EFFECTIVENESS OF RIVAROXABAN WITHIN SUBGROUPS FOR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM IN THE NETHERLANDS

被引：0
|
作者：
Gout-Zwart, J. [1 ]
Sediq, A. [1 ]
van den Bosch, M. [2 ]
Postma, M. J. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Bayer BV, Mijdrecht, Netherlands
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1758
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV90
引用
收藏
页码：A652 / A652
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands
    Heisen, Marieke
    Treur, Maarten J.
    Heemstra, Harald E.
    Giesen, Eric B. W.
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 813 - 824
  • [2] Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis
    de Jong, Lisa Aniek
    Gout-Zwart, Judith J.
    van den Bosch, Marina
    Koops, Mike
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 306 - 318
  • [3] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED TO WARFARIN FOR STROKE PROPHYLAXIS IN ATRIAL FIBRILLATION
    Lee, Soyon
    Anglade, Moise
    Pisacane, Robyn
    Pham, Dan
    Kluger, Jeffrey
    Coleman, Craig
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E600 - E600
  • [4] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Kapur, A. K.
    Chatzitheofilou, I
    Schang, L. K.
    VALUE IN HEALTH, 2012, 15 (04) : A122 - A122
  • [5] Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
    Lee, Soyon
    Anglade, Moise W.
    Dan Pham
    Pisacane, Robyn
    Kluger, Jeffrey
    Coleman, Craig I.
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (06): : 845 - 851
  • [6] Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
    Morais, Joao
    Aguiar, Carlos
    McLeod, Euan
    Chatzitheofilou, Ismini
    Santos, Isabel Fonseca
    Pereira, Sonia
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2014, 33 (09) : 535 - 544
  • [7] Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada
    Diamantopoulos, Alexander
    Lees, Michael
    Wells, Philip S.
    Forster, Fiona
    Ananthapavan, Jaithri
    McDonald, Heather
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (04) : 760 - 770
  • [8] COST-EFFECTIVENESS ANALYSIS OF APIXABAN AND RIVAROXABAN FOR TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN CHINA
    Gu, X.
    Wu, B.
    VALUE IN HEALTH, 2017, 20 (09) : A618 - A618
  • [9] Features and practical use of rivaroxaban in atrial fibrillation and venous thromboembolism
    Imberti, Davide
    Agnelli, Giancarlo
    Andreotti, Felicita
    Dentali, Francesco
    Gensini, Gian Franco
    Landolfi, Raffaele
    Micieli, Giuseppe
    Prisco, Domenico
    GIORNALE ITALIANO DI CARDIOLOGIA, 2014, 15 (06) : 3S - 22S
  • [10] THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION (AF) IN TURKEY
    Marmarali, B.
    Ozdemir, O.
    Bozkurt, K.
    Demir, M.
    Ince, B.
    Kultursay, H.
    Ongen, G.
    Ongen, Z.
    Deger, C.
    Ozel, M. O.
    Parali, E.
    Sumer, F.
    Tuna, E.
    Yilmaz, Z. S.
    VALUE IN HEALTH, 2013, 16 (03) : A285 - A285
12345